AlpinaBioTech Digest - August 2026

This month's six articles center heavily on biosimilar monitoring, where the measurement questions are becoming more pressing as real-world switching data accumulate without systematic therapeutic drug monitoring or anti-drug antibody testing built in. Two pieces examine anti-TNF and anti-CD20 biosimilars directly: one reviews what a post-switch trough level drop in pediatric adalimumab cohorts means for laboratory protocols, and another draws on the BRAVO multicenter cohort to argue that equivalent six-month clinical outcomes in rituximab-treated AAV patients reinforce, rather than reduce, the rationale for structured pharmacokinetic and immunogenicity monitoring. All assays and products described are for Research Use Only.

Two further articles address the interpretation and technical integrity of ADA assays themselves. A methodological piece works through why a highly sensitive immunogenicity platform can return an ADA incidence figure several times higher than a reference biologic's labeled rate, and what assay sensitivity, drug tolerance, and platform architecture each contribute to that number. A case study on Gyrolab-based ADA testing with a rituximab biosimilar traces wave-like signal artifacts to neutralization buffer chemistry and fluorophore-induced isoelectric point shifts, offering troubleshooting principles transferable across any laboratory running microfluidic immunogenicity programs. A fifth article maps the analytical characterization strategies that now underpin regulatory approval of mAb biosimilars in the US and EU, grounding the discussion in a recent FDA clinical efficacy study waiver for a ustekinumab biosimilar.

Stepping outside the biosimilar space, we also cover a high-sensitivity biosensor for circulating ESAT-6, a secretory protein of Mycobacterium tuberculosis, that distinguished active disease from latent infection and uninfected contacts with an AUC of 0.976 in a 217-patient cohort presented at ADLM 2026. Because this is an antigen-direct measurement rather than a host immune response readout, it occupies a different analytical position from IGRAs, and that distinction has practical implications for laboratory test design. Full analytical validation and prospective clinical data remain outstanding, and the findings are conference-reported pending peer-reviewed publication.